# A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia

> **NCT05232149** · PHASE2 · UNKNOWN · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Primary Immune Thrombocytopenia

## Interventions

- **DRUG:** Orelabrutinib( lower dose)
- **DRUG:** Orelabrutinib( higher dose)

## Key facts

- **NCT ID:** NCT05232149
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-21
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05232149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05232149, "A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05232149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*